Skip to main content
. 2020 Apr 6;10(12):5169–5180. doi: 10.7150/thno.43231

Figure 4.

Figure 4

In vivo and ex vivo BLI analysis of Toledo-Luci disseminated mice treated with buffer or T22-PE24-H6 therapeutic nanoparticle. (A) Experimental design followed along the in vivo experiment. (B) Representative images of mice with disseminated lymphoma registered by IVIS Spectrum (BLI signal) at day 21, 28, and 33 after Toledo-Luci cells IV injection in mice treated with buffer or T22-PE24-H6. (C) BLI quantification over the experimental time in mice treated with buffer (n=9) or T22-PE24-H6 (n=9). (D) Body weight of mice treated with buffer or T22-PE24-H6 during the treatment period. (E) Ex vivo BLI quantitation (left) and representative images (right) of lymphoma-infiltrated organs (cervical LNs, renal LNs and BM) for both groups at the end of the experiment. Results are expressed as mean ± SE. BLI: bioluminescence imaging (total flux); BM: bone marrow; IV: intravenous; LNs: lymph nodes; *p≤0.05; **p≤0.01; ***p≤0.005.